Interleukin-4 can be a key positive regulator of inflammatory arthritis

Arthritis and Rheumatism

Volumn 52, Issue 6, 2005, Pages 1866-1875

  Ohmura, Koichiro ^a   Nguyen, Linh T ^a   Locksley, Richard M ^b   Mathis, Diane ^a   Benoist, Christophe ^a,c  

^a BRIGHAM AND WOMEN S HOSPITAL   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c JOSLIN DIABETES CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

GLUCOSE 6 PHOSPHATE ISOMERASE; GREEN FLUORESCENT PROTEIN; INTERLEUKIN 12; INTERLEUKIN 12P35; INTERLEUKIN 4; T LYMPHOCYTE RECEPTOR; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIBODY RESPONSE; ANTIBODY TITER; ARTHRITIS; ARTICLE; CYTOKINE PRODUCTION; EOSINOPHIL; GENE CONTROL; LYMPHOCYTE DIFFERENTIATION; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; T LYMPHOCYTE; TH1 CELL; TH2 CELL;

ANIMALS; ARTHRITIS; ARTHRITIS, RHEUMATOID; AUTOANTIBODIES; AUTOIMMUNE DISEASES; CELL DIFFERENTIATION; INTERLEUKIN-12; INTERLEUKIN-4; MICE; TH1 CELLS; TH2 CELLS;

EID: 20744453370     PISSN: 00043591     EISSN: None     Source Type: Journal    
DOI: 10.1002/art.21104     Document Type: Article

References (49)

1. Feldmann M, Brennan FM, Maini RN. Role of cytokines in rheumatoid arthritis [review]. Annu Rev Immunol 1996;14: 397-440.
2. Bresnihan B, Alvaro-Gracia JM, Cobby M, Doherty M, Domljan Z, Emery P, et al. Treatment of rheumatoid arthritis with recombinant human interleukin-1 receptor antagonist. Arthritis Rheum 1998;41:2196-204.
3. Bathon JM, Martin RW, Fleischmann RM, Tesser JR, Schiff MH, Keystone EC, et al. A comparison of etanercept and methotrexate in patients with early rheumatoid arthritis [published erratum appears in N Engl J Med 2001;344:240]. N Engl J Med 2000;343: 1586-93.
4. Lipsky PE, van der Heijde DM, St. Clair EW, Furst DE, Breedveld FC, Kalden JR, et al, for the Anti-Tumor Necrosis Factor Trial in Rheumatoid Arthritis with Concomitant Therapy Study Group. Infliximab and methotrexate in the treatment of rheumatoid arthritis. N Engl J Med 2000;343:1594-602.
5. Nishimoto N, Yoshizaki K, Miyasaka N, Yamamoto K, Kawai S, Takeuchi T, et al. Treatment of rheumatoid arthritis with humanized anti-interleukin-6 receptor antibody: a multicenter, double-blind, placebo-controlled trial. Arthritis Rheum 2004;50:1761-9.
6. Miossec P, van den Berg W. Th1/Th2 cytokine balance in arthritis [review]. Arthritis Rheum 1997;40:2105-15.
7. Sigidin YA, Loukina GV, Skurkovich B, Skurkovich S. Randomized, double-blind trial of anti-interferon-γ antibodies in rheumatoid arthritis. Scand J Rheumatol 2001;30:203-7.
8. Nelms K, Keegan AD, Zamorano J, Ryan JJ, Paul WE. The IL-4 receptor: signaling mechanisms and biologic functions [review]. Annu Rev Immunol 1999;17:701-38.
9. Essner R, Rhoades K, McBride WH, Morton DL, Economou JS. IL-4 down-regulates IL-1 and TNF gene expression in human monocytes. J Immunol 1989;142:3857-61.
10. Hart PH, Vitti GF, Burgess DR, Whitty GA, Piccoli DS, Hamilton JA. Potential antiinflammatory effects of interleukin 4: suppression of human monocyte tumor necrosis factor α, interleukin 1, and prostaglandin E2. Proc Natl Acad Sci USA 1989;86:3803-7.
11. Dechanet J, Briolay J, Rissoan MC, Chomarat P, Galizzi JP, Banchereau J, et al. IL-4 inhibits growth factor-stimulated rheumatoid synoviocyte proliferation by blocking the early phases of the cell cycle. J Immunol 1993;151:4908-17.
12. Gately MK, Renzetti LM, Magram J, Stern AS, Adorini L, Gubler U, et al. The interleukin-12/interleukin-12-receptor system: role in normal and pathologic immune responses [review]. Annu Rev Immunol 1998;16:495-521.
13. Ortmann RA, Shevach EM. Susceptibility to collagen-induced arthritis: cytokine-mediated regulation. Clin Immunol 2001;98: 109-18.
14. Svensson L, Nandakumar KS, Johansson A, Jansson L, Holmdahl R. IL-4-deficient mice develop less acute but more chronic relapsing collagen-induced arthritis. Eur J Immunol 2002;32:2944-53.
15. Myers LK, Tang B, Stuart JM, Kang AH. The role of IL-4 in regulation of murine collagen-induced arthritis. Clin Immunol 2002;102:185-91.
16. Finnegan A, Mikecz K, Tao P, Giant TT. Proteoglycan (aggrecan)-induced arthritis in BALB/c mice is a Th1-type disease regulated by Th2 cytokines. J Immunol 1999;163:5383-90.
17. Finnegan A, Grusby MJ, Kaplan CD, O'Neill SK, Eibel H, Koreny T, et al. IL-4 and IL-12 regulate proteoglycan-induced arthritis through Stat-dependent mechanisms. J Immunol 2002;169: 3345-52.
18. Matthys P, Vermeire K, Mitera T, Heremans H, Huang S, Billiau A. Anti-IL-12 antibody prevents the development and progression of collagen-induced arthritis in IFN-γ receptor-deficient mice. Eur J Immunol 1998;28:2143-51.
19. Malfait AM, Butler DM, Presky DH, Maini RN, Brennan FM, Feldmann M. Blockade of IL-12 during the induction of collagen-induced arthritis (CIA) markedly attenuates the severity of the arthritis. Clin Exp Immunol 1998;111:377-83.
20. Murphy CA, Langrish CL, Chen Y, Blumenschein W, McClanahan T, Kastelein RA, et al. Divergent pro- and antiinflammatory roles for IL-23 and IL-12 in joint autoimmune inflammation. J Exp Med 2003;198:1951-7.
21. Kouskoff V, Korganow AS, Duchatelle V, Degott C, Benoist C, Mathis D. Organ-specific disease provoked by systemic autoimmunity. Cell 1996;87:811-22.
22. Ji H, Pettit A, Ohmura K, Ortiz-Lopez A, Duchatelle V, Degott C, et al. Critical roles for interleukin-1 and tumor necrosis factor α in antibody-induced arthritis. J Exp Med 2002;196:77-85.
23. Ji H, Ohmura K, Mahmood U, Lee DM, Hofhuis FM, Boackle SA, et al. Arthritis critically dependent on innate immune system players. Immunity 2002;16:157-68.
24. Matsumoto I, Staub A, Benoist C, Mathis D. Arthritis provoked by linked T and B cell recognition of a glycolytic enzyme. Science 1999;286:1732-5.
25. Maccioni M, Zeder-Lutz G, Huang H, Ebel C, Gerber P, Hergueux J, et al. Arthritogenic monoclonal antibodies from K/BxN mice. J Exp Med 2002;195:1071-7.
26. Korganow AS, Ji H, Mangialaio S, Duchatelle V, Pelanda R, Martin T, et al. From systemic T cell self-reactivity to organ-specific autoimmune disease via immunoglobulins. Immunity 1999;10:451-61.
27. Metwali A, Elliott D, Blum AM, Li J, Sandor M, Lynch R, et al. The granulomatous response in murine Schistosomiasis mansoni does not switch to Th1 in IL-4-deficient C57BL/6 mice. J Immunol 1996;157:4546-53.
28. Philpott KL, Viney JL, Kay G, Rastan S, Gardiner EM, Chae S, et al. Lymphoid development in mice congenitally lacking T cell receptor αβ-expressing cells. Science 1992;256:1448-52.
29. Mattner F, Magram J, Ferrante J, Launois P, di Padova K, Behin R, et al. Genetically resistant mice lacking interleukin-12 are susceptible to infection with Leishmania major and mount a polarized Th2 cell response. Eur J Immunol 1996;26:1553-9.
30. Mohrs M, Shinkai K, Mohrs K, Locksley RM. Analysis of type 2 immunity in vivo with a bicistronic IL-4 reporter. Immunity 2001;15:303-11.
31. Morgado MG, Cam P, Gris-Liebe C, Cazenave PA, Jouvin-Marche E. Further evidence that BALB/c and C57BL/6 γ2a genes originate from two distinct isotypes. EMBO J 1989;8:3245-51.
32. Mangialaio S, Ji H, Korganow AS, Kouskoff V, Benoist C, Mathis D. The arthritogenic T cell receptor and its ligand in a model of spontaneous arthritis. Arthritis Rheum 1999;42:2517-23.
33. McKenzie GJ, Fallon PG, Emson CL, Grencis RK, McKenzie AN. Simultaneous disruption of interleukin (IL)-4 and IL-13 defines individual roles in T helper cell type 2-mediated responses. J Exp Med 1999;189:1565-72.
34. Matsumoto I, Maccioni M, Lee DM, Maurice M, Simmons B, Brenner M, et al. How antibodies to a ubiquitous cytoplasmic enzyme may provoke joint-specific autoimmune disease. Nat Immunol 2002;3:360-5.
35. Mosmann TR, Coffman RL. TH1 and TH2 cells: different patterns of lymphokine secretion lead to different functional properties [review]. Annu Rev Immunol 1989;7:145-73.
36. Rosloniec EF, Latham K, Guedez YB. Paradoxical roles of IFN-γ in models of Th1-mediated autoimmunity [review]. Arthritis Res 2002;4:333-6.
37. Lassmann H, Ransohoff RM. The CD4-Th1 model for multiple sclerosis: a crucial re-appraisal [published erratum appears in Trends Immunol 2004;25:275]. Trends Immunol 2004;25:132-7.
38. Chu CQ, Wittmer S, Dalton DK. Failure to suppress the expansion of the activated CD4 T cell population in interferon γ-deficient mice leads to exacerbation of experimental autoimmune encephalomyelitis. J Exp Med 2000;192:123-8.
39. Furlan R, Brambilla E, Ruffini F, Poliani PL, Bergami A, Marconi PC, et al. Intrathecal delivery of IFN-γ protects C57BL/6 mice from chronic-progressive experimental autoimmune encephalomyelitis by increasing apoptosis of central nervous system-infiltrating lymphocytes. J Immunol 2001;167:1821-9.
40. Coffman RL, Seymour BW, Lebman DA, Hiraki DD, Christiansen JA, Shrader B, et al. The role of helper T cell products in mouse B cell differentiation and isotype regulation [review]. Immunol Rev 1988;102:5-28.
41. Hata H, Sakaguchi N, Yoshitomi H, Iwakura Y, Sekikawa K, Azuma Y, et al. Distinct contribution of IL-6, TNF-α, IL-1, and IL-10 to T cell-mediated spontaneous autoimmune arthritis in mice. J Clin Invest 2004;114:582-8.
42. Monach PA, Benoist C, Mathis D. The role of antibodies in mouse models of rheumatoid arthritis, and relevance to human disease [review]. Adv Immunol 2004;82:217-48.
43. Silverman GJ, Weisman S. Rituximab therapy and autoimmune disorders: prospects for anti-B cell therapy [review]. Arthritis Rheum 2003;48:1484-92.
44. Schaller M, Burton DR, Ditzel HJ. Autoantibodies to GPI in rheumatoid arthritis: linkage between an animal model and human disease. Nat Immunol 2001;2:746-53.
45. Matsumoto I, Lee DM, Goldbach-Mansky R, Sumida T, Hitchon CA, Schur PH, et al. Low prevalence of antibodies to glucose-6-phosphate isomerase in patients with rheumatoid arthritis and a spectrum of other chronic autoimmune disorders. Arthritis Rheum 2003;48:944-54.
46. Van Gaalen FA, Toes RE, Ditzel HJ, Schaller M, Breedveld FC, Verweij CL, et al. Association of autoantibodies to glucose-6-phosphate isomerase with extraarticular complications in rheumatoid arthritis. Arthritis Rheum 2004;50:395-9.
47. Cohen PL, Cheek RL, Hadler JA, Yount WJ, Eisenberg RA. The subclass distribution of human IgG rheumatoid factor. J Immunol 1987;139:1466-71.
48. Persselin JE, Stevens RH. Anti-Fab antibodies in humans: predominance of minor immunoglobulin G subclasses in rheumatoid arthritis. J Clin Invest 1985;76:723-30.
49. Ghoreschi K, Thomas P, Breit S, Dugas M, Mailhammer R, van Eden W, et al. Interleukin-4 therapy of psoriasis induces Th2 responses and improves human autoimmune disease. Nat Med 2003;9:40-6.